lansoprazole has been researched along with Breast Cancer in 4 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, treatment of human breast cancer cells with proton pump inhibitor (PPI) lansoprazole (LPZ) induces cell apoptosis in a dose-dependent manner." | 7.80 | Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion. ( Li, SJ; Wang, Y; Zhang, S, 2014) |
| " Here, treatment of human breast cancer cells with proton pump inhibitor (PPI) lansoprazole (LPZ) induces cell apoptosis in a dose-dependent manner." | 3.80 | Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion. ( Li, SJ; Wang, Y; Zhang, S, 2014) |
| "Among the 48 human ABC proteins, the breast cancer resistance protein (BCRP/ABCG2) has been described as a pivotal player in cancer resistance." | 2.82 | Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. ( Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF, 2022) |
| "Lansoprazole was not toxic to cancer cells but potentiated the cytotoxicity of doxorubicin and enhanced its penetration through multilayered cell cultures." | 1.42 | Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors. ( Lee, C; Tannock, IF; Wang, M; Yu, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zattoni, IF | 1 |
| Delabio, LC | 1 |
| Dutra, JP | 1 |
| Kita, DH | 1 |
| Scheiffer, G | 1 |
| Hembecker, M | 1 |
| Pereira, GDS | 1 |
| Moure, VR | 1 |
| Valdameri, G | 1 |
| Wang, CJ | 1 |
| Li, D | 1 |
| Danielson, JA | 1 |
| Zhang, EH | 1 |
| Dong, Z | 1 |
| Miller, KD | 1 |
| Li, L | 1 |
| Zhang, JT | 1 |
| Liu, JY | 1 |
| Zhang, S | 1 |
| Wang, Y | 1 |
| Li, SJ | 1 |
| Yu, M | 1 |
| Lee, C | 1 |
| Wang, M | 1 |
| Tannock, IF | 1 |
1 review available for lansoprazole and Breast Cancer
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Dr | 2022 |
3 other studies available for lansoprazole and Breast Cancer
| Article | Year |
|---|---|
Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Chemoradiotherapy; Data | 2021 |
Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Hydr | 2014 |
Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors.
Topics: Animals; Antibiotics, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Pr | 2015 |